Medtronic, a medical technology provider, has announced CE Mark approval for its BrainSense Adaptive Deep Brain Stimulation (aDBS) system and BrainSense Electrode Identifier in the European Union and the UK. This milestone highlights advancements in personalized treatment for Parkinson's disease, with the first programming in Europe already completed by Martijn Beudel at Amsterdam University Medical Center. The BrainSense aDBS system adapts therapy in real time based on individual brain activity, offering a dynamic approach to managing Parkinson’s symptoms. The Electrode Identifier further enhances precision by pinpointing optimal stimulation contact points, reducing setup time, and improving efficiency.
Parkinson’s disease affects more than 10 million people globally, including 1.2 million in Europe. Medtronic's BrainSense technology aims to address this challenge by tailoring deep brain stimulation to patients’ unique neurological patterns. The CE Mark approval is supported by extensive clinical trials, including the ADAPT-PD study, which demonstrated the system’s safety and effectiveness in real-world settings. The technology will be available in Europe in early 2025, with FDA approval pending for U.S. distribution.
